Rosalind Advisors’s Ocular Therapeutix OCUL Stock Holding History

Rosalind Advisors’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-400,000	Closed	-$4.86M	–	39
2025 Q4	$4.86M	Hold	400,000	–	–	1.71%	18
2025 Q3	$4.68M	Sell	400,000 -818,700	-67%	-$9.79M	1.6%	21
2025 Q2	$11.3M	Hold	1,218,700	–	–	5.36%	4
2025 Q1	$8.93M	Buy	1,218,700 +90,000	+8%	+$692K	4.34%	8
2024 Q4	$9.64M	Buy	1,128,700 +243,700	+28%	+$2.38M	4.93%	7
2024 Q3	$7.7M	Buy	885,000 +135,000	+18%	+$1.11M	4.93%	10
2024 Q2	$5.13M	Buy	+750,000	New	+$4.63M	3.95%	10

Other funds holding OCUL

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Rosalind Advisors's OCUL Position: Q1 2026 in Review

Rosalind Advisors sold out of Ocular Therapeutix (OCUL) in Q1 2026, closing a stake of 400,000 shares — an estimated $4.86M sold.

Rosalind Advisors first reported a position in OCUL in Q2 2024 and held it in 7 quarters. The position peaked at $11.3M in Q2 2025. 269 funds tracked by Wall St. Rank hold OCUL as of Q1 2026.

Rosalind Advisors reported no remaining Ocular Therapeutix position as of Q1 2026 after selling out during the quarter.
Rosalind Advisors sold 400,000 Ocular Therapeutix shares in Q1 2026, an estimated $4.86M.
Rosalind Advisors first reported a position in Ocular Therapeutix in Q2 2024 and held it in 7 quarters.
Rosalind Advisors's Ocular Therapeutix position peaked at $11.3M in Q2 2025.
269 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q1 2026.

Based on Rosalind Advisors's 13F filing for Q1 2026, filed 14 May 2026.